Related Experiment Video

Updated: Jul 19, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies

Jyoti D Patel1

  • 1Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA. jd-patel@northwestern.edu

Current Opinion in Oncology
|September 22, 2006
PubMed
Abstract

Insights

Epidermal growth factor receptor (EGFR) inhibitors show promise in treating nonsmall-cell lung cancer and head and neck cancers. These targeted therapies are advancing patient care and driving further clinical research.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The epidermal growth factor receptor (EGFR) pathway is integral to carcinogenesis, influencing cell proliferation, differentiation, apoptosis, metastasis, and angiogenesis.
  • Dysregulation of the EGFR pathway is implicated in the development and progression of various cancers.

Purpose of the Study:

  • To review the progress in utilizing epidermal growth factor receptor (EGFR) inhibitors for nonsmall-cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (HNSCC).
  • To discuss recent findings on the clinical activity of EGFR inhibitors and associated sensitivity markers.

Main Methods:

  • Review of current literature on EGFR inhibitors in NSCLC and HNSCC.
  • Analysis of clinical trial data and research on predictive biomarkers for EGFR-targeted therapy.

Main Results:

  • Anti-EGFR agents, including monoclonal antibodies and small molecule tyrosine kinase inhibitors, target key domains of the EGFR pathway.
  • Both therapeutic strategies have yielded encouraging results as monotherapies and in combination with standard treatments like chemotherapy and radiotherapy in aerodigestive malignancies.
  • Significant clinical activity has been observed in patients with NSCLC and HNSCC.

Conclusions:

  • The success of EGFR inhibitors has spurred further clinical investigations in aerodigestive malignancies.
  • EGFR-targeted therapy is making a substantial impact on the clinical management of patients diagnosed with NSCLC and HNSCC.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...